SCHEMBL18965124

SCHEMBL18965124

CC1(F)CN(C(=O)Cn2ccc3scc(-c4ccc(F)c(Cl)c4)c3c2=O)C1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EPHB4 P54760 1/20 0.41
GRIN2B Q13224 16/20 0.40
ALDH1A1 P00352 1/20 0.38
GRIN1 Q05586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30219967 1.00 EPHB4 (0.41) EPHB4GRIN2BALDH1A1GRIN1
SCHEMBL18965060 0.93 GRIN2B (0.42) EPHB4GRIN2BALDH1A1GRIN1
SCHEMBL18965119 0.93 ALDH1A1 (0.39) GRIN2BALDH1A1GRIN1
SCHEMBL30219980 0.93 GRIN2B (0.42) EPHB4GRIN2BALDH1A1GRIN1
SCHEMBL18964497 0.93 GRIN2B (0.44) EPHB4GRIN2BGRIN1
SCHEMBL30219868 0.93 GRIN2B (0.44) EPHB4GRIN2BGRIN1
SCHEMBL30220106 0.93 ALDH1A1 (0.39) GRIN2BALDH1A1
SCHEMBL18964795 0.93 ALDH1A1 (0.39) GRIN2BALDH1A1
SCHEMBL30220034 0.92 EPHB4 (0.40) EPHB4GRIN2BALDH1A1GRIN1
SCHEMBL18965056 0.92 EPHB4 (0.40) EPHB4GRIN2BALDH1A1GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3830092-B1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-05-03 EP disclosed
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-01-26 US disclosed
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2023-01-26 US disclosed
US-11542264-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2023-01-03 US disclosed
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2022-02-01 US disclosed
US-20210403474-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2021-12-30 US disclosed
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2021-04-15 US disclosed
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2021-04-15 US disclosed
US-10752633-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2020-08-25 US disclosed
EP-3386591-B1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF CADENT THERAPEUTICS INC (US) 2020-06-24 EP disclosed
EP-3386591-B1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF CADENT THERAPEUTICS INC (US) 2020-06-24 EP disclosed
US-20200131190-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2020-04-30 US disclosed
US-10626122-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2020-04-21 US disclosed
US-10626122-B2 Heteroaromatic NMDA receptor modulators and uses thereof CADENT THERAPEUTICS, INC. (US) 2020-04-21 US disclosed
US-20200039987-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2020-02-06 US disclosed
US-20180362541-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF NOVARTIS AG (CH) 2018-12-20 US disclosed
WO-2017100591-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF LUC THERAPEUTICS (US) 2017-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039987-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN3A, GRIN2A EPHB4 1906/4885GRIN2B 6/4885ALDH1A1 2360/4885
US-11236104-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN2A, GRIN1 EPHB4 1894/4885GRIN2B 5/4885ALDH1A1 1771/4885
US-10626122-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN2A, GRIN1 EPHB4 1894/4885GRIN2B 5/4885ALDH1A1 1771/4885
US-20180362541-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 EPHB4 1894/4885GRIN2B 5/4885ALDH1A1 1771/4885
US-20200131190-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN3A, GRIN2A EPHB4 1906/4885GRIN2B 6/4885ALDH1A1 2360/4885
US-20210403474-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN3A, GRIN2A EPHB4 1906/4885GRIN2B 6/4885ALDH1A1 2360/4885
US-11542264-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN3A, GRIN2A EPHB4 1906/4885GRIN2B 6/4885ALDH1A1 2360/4885
US-20230023543-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 EPHB4 1894/4885GRIN2B 5/4885ALDH1A1 1771/4885
US-20210107916-A1 HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN2C, GRIN2A, GRIN1 EPHB4 1894/4885GRIN2B 5/4885ALDH1A1 1771/4885
US-10752633-B2 Heteroaromatic NMDA receptor modulators and uses thereof GRIN2C, GRIN3A, GRIN2A EPHB4 1906/4885GRIN2B 6/4885ALDH1A1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.